Sapna Pradyuman Patel

机构：Maharaja Sayajirao University of Baroda, University of Colorado Hospital, The University of Texas MD Anderson Cancer Center, University of Colorado Boulder, University of Colorado Cancer Center, University of Colorado Anschutz, JSS Dental College and Hospital, University of Colorado Denver · ORCID：0000-0003-1339-1517

发表论文 476 篇 · 总被引 22159 次 · h-index 51

代表论文

• Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma (2025 · Journal of Clinical Oncology · 被引 15)
• Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure (2025 · ESMO Open · 被引 9)
• 1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial (2025 · Annals of Oncology · 被引 7)
• Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma (2025 · OncoImmunology · 被引 7)
• Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial (2025 · Nature Medicine · 被引 6)
• 1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801 (2025 · Annals of Oncology · 被引 5)